This is a branding and awareness initiative with no immediate financial implications. Traders should monitor for future updates on commercial or clinical progress, but this release alone is unlikely to move the stock meaningfully.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 7 $1.29entry
- T+1 · 7mo ago +4.65%α +2.11% · $1.35
- T+5 · 7mo ago +24.81%α +19.48% · $1.61
- T+20 · 7mo ago +13.95%α +4.17% · $1.47
- T+60 · 5mo ago −30.71%α −43.98% · $0.8938
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd launched a national education campaign called 'Antibodies for Any Body' in partnership with ski champion Lindsey Vonn to raise public awareness about antibodies and immune health. The campaign features a dedicated website with an interactive wellness assessment tool to help individuals understand how lifestyle habits influence immune function. This is a promotional initiative and does not involve a commercial product launch or financial transaction.
Key Facts
- Invivyd launched a public education campaign focused on antibodies and immune health.
- The campaign includes a partnership with Olympic skier Lindsey Vonn.
- A new website, AntibodiesforAnyBody.com, offers an interactive immune health assessment tool.
- No financial figures, product sales, or clinical data were disclosed in the release.
- The announcement is promotional and includes forward-looking statements with no material financial impact.
Financial Impact
No direct financial impact disclosed; campaign is educational and brand-building in nature.
Risk Factors
- Forward-looking statements are subject to risks including execution risk for the campaign.
- No assurance the campaign will lead to increased product adoption or revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3268977 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers